200 related articles for article (PubMed ID: 35148403)
1. Tumor-related molecular determinants of neurocognitive deficits in patients with diffuse glioma.
van Kessel E; Berendsen S; Baumfalk AE; Venugopal H; Krijnen EA; Spliet WGM; van Hecke W; Giuliani F; Seute T; van Zandvoort MJE; Snijders TJ; Robe PA
Neuro Oncol; 2022 Oct; 24(10):1660-1670. PubMed ID: 35148403
[TBL] [Abstract][Full Text] [Related]
2. Neurocognitive changes after awake surgery in glioma patients: a retrospective cohort study.
van Kessel E; Snijders TJ; Baumfalk AE; Ruis C; van Baarsen KM; Broekman ML; van Zandvoort MJE; Robe PA
J Neurooncol; 2020 Jan; 146(1):97-109. PubMed ID: 31802314
[TBL] [Abstract][Full Text] [Related]
3. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a retrospective cohort study prior to antitumor treatment.
van Kessel E; Emons MAC; Wajer IH; van Baarsen KM; Broekman ML; Robe PA; Snijders TJ; Van Zandvoort MJE
Neurooncol Pract; 2019 Dec; 6(6):463-472. PubMed ID: 31832216
[TBL] [Abstract][Full Text] [Related]
4. Tumor-related neurocognitive dysfunction in patients with diffuse glioma: a systematic review of neurocognitive functioning prior to anti-tumor treatment.
van Kessel E; Baumfalk AE; van Zandvoort MJE; Robe PA; Snijders TJ
J Neurooncol; 2017 Aug; 134(1):9-18. PubMed ID: 28567586
[TBL] [Abstract][Full Text] [Related]
5. Cognitive impairments are independently associated with shorter survival in diffuse glioma patients.
van Kessel E; Huenges Wajer IMC; Ruis C; Seute T; Fonville S; De Vos FYFL; Verhoeff JJC; Robe PA; van Zandvoort MJE; Snijders TJ
J Neurol; 2021 Apr; 268(4):1434-1442. PubMed ID: 33211158
[TBL] [Abstract][Full Text] [Related]
6. Neurocognitive function varies by IDH1 genetic mutation status in patients with malignant glioma prior to surgical resection.
Wefel JS; Noll KR; Rao G; Cahill DP
Neuro Oncol; 2016 Dec; 18(12):1656-1663. PubMed ID: 27576872
[TBL] [Abstract][Full Text] [Related]
7. Relationships between tumor grade and neurocognitive functioning in patients with glioma of the left temporal lobe prior to surgical resection.
Noll KR; Sullaway C; Ziu M; Weinberg JS; Wefel JS
Neuro Oncol; 2015 Apr; 17(4):580-7. PubMed ID: 25227126
[TBL] [Abstract][Full Text] [Related]
8. Objective neurocognitive functioning and neurocognitive complaints in patients with high-grade glioma: Evidence of cognitive awareness from the European Organisation for Research and Treatment of Cancer brain tumour clinical trials.
Caramanna I; Bottomley A; Drijver AJ; Twisk J; van den Bent M; Idbaih A; Wick W; Pe M; Klein M; Reijneveld JC;
Eur J Cancer; 2021 Feb; 144():162-168. PubMed ID: 33348088
[TBL] [Abstract][Full Text] [Related]
9. Association between tumor location and neurocognitive functioning using tumor localization maps.
Habets EJJ; Hendriks EJ; Taphoorn MJB; Douw L; Zwinderman AH; Vandertop WP; Barkhof F; De Witt Hamer PC; Klein M
J Neurooncol; 2019 Sep; 144(3):573-582. PubMed ID: 31410731
[TBL] [Abstract][Full Text] [Related]
10. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas.
Akyerli CB; Yüksel Ş; Can Ö; Erson-Omay EZ; Oktay Y; Coşgun E; Ülgen E; Erdemgil Y; Sav A; von Deimling A; Günel M; Yakıcıer MC; Pamir MN; Özduman K
J Neurosurg; 2018 Apr; 128(4):1102-1114. PubMed ID: 28621624
[TBL] [Abstract][Full Text] [Related]
11. Association between objective neurocognitive functioning and neurocognitive complaints in recurrent high-grade glioma: Longitudinal evidence of cognitive awareness from EORTC brain tumour trials.
Caramanna I; Reijneveld JC; van de Ven PM; van den Bent M; Idbaih A; Wick W; Taphoorn MJB; Dirven L; Bottomley A; Klein M;
Eur J Cancer; 2023 Jun; 186():38-51. PubMed ID: 37028200
[TBL] [Abstract][Full Text] [Related]
12. PI3 kinase mutations and mutational load as poor prognostic markers in diffuse glioma patients.
Draaisma K; Wijnenga MM; Weenink B; Gao Y; Smid M; Robe P; van den Bent MJ; French PJ
Acta Neuropathol Commun; 2015 Dec; 3():88. PubMed ID: 26699864
[TBL] [Abstract][Full Text] [Related]
13. IDH mutation and neuroglial developmental features define clinically distinct subclasses of lower grade diffuse astrocytic glioma.
Gorovets D; Kannan K; Shen R; Kastenhuber ER; Islamdoust N; Campos C; Pentsova E; Heguy A; Jhanwar SC; Mellinghoff IK; Chan TA; Huse JT
Clin Cancer Res; 2012 May; 18(9):2490-501. PubMed ID: 22415316
[TBL] [Abstract][Full Text] [Related]
14. Pre-operative Neurocognitive Function Was More Susceptible to Decline in Isocitrate Dehydrogenase Wild-Type Subgroups of Lower-Grade Glioma Patients.
Zhang Z; Jin Z; Yang X; Zhang L; Zhang Y; Liu D; Chi X; Hao S; Feng J; Ji N
Front Neurol; 2020; 11():591615. PubMed ID: 33363506
[No Abstract] [Full Text] [Related]
15. Genetic modulation of longitudinal change in neurocognitive function among adult glioma patients.
Wefel JS; Zhou R; Sulman EP; Boehling NS; Armstrong GN; Tsavachidis S; Liang FW; Etzel CJ; Kahalley LS; Small BJ; Scheurer ME; Bondy ML; Liu Y
J Neurooncol; 2022 Jan; 156(1):185-193. PubMed ID: 34817796
[TBL] [Abstract][Full Text] [Related]
16. Immunohistochemistry on IDH 1/2, ATRX, p53 and Ki-67 substitute molecular genetic testing and predict patient prognosis in grade III adult diffuse gliomas.
Takano S; Ishikawa E; Sakamoto N; Matsuda M; Akutsu H; Noguchi M; Kato Y; Yamamoto T; Matsumura A
Brain Tumor Pathol; 2016 Apr; 33(2):107-16. PubMed ID: 26968173
[TBL] [Abstract][Full Text] [Related]
17. Molecular Determinants of Neurocognitive Deficits in Glioma: Based on 2021 WHO Classification.
Zhang K; Yang T; Xia Y; Guo X; Chen W; Wang L; Li J; Wu J; Xiao Z; Zhang X; Jiang W; Xu D; Guo S; Wang Y; Shi Y; Liu D; Li Y; Wang Y; Xing H; Liang T; Niu P; Wang H; Liu Q; Jin S; Qu T; Li H; Zhang Y; Ma W; Wang Y
J Mol Neurosci; 2024 Feb; 74(1):17. PubMed ID: 38315329
[TBL] [Abstract][Full Text] [Related]
18. Tumour and surgery effects on cognitive functioning in high-grade glioma patients.
Habets EJ; Kloet A; Walchenbach R; Vecht CJ; Klein M; Taphoorn MJ
Acta Neurochir (Wien); 2014 Aug; 156(8):1451-9. PubMed ID: 24879620
[TBL] [Abstract][Full Text] [Related]
19. Cognitive functioning early after surgery of gliomas in eloquent areas.
Satoer D; Vork J; Visch-Brink E; Smits M; Dirven C; Vincent A
J Neurosurg; 2012 Nov; 117(5):831-8. PubMed ID: 22937930
[TBL] [Abstract][Full Text] [Related]
20. ATRX immunostaining predicts IDH and H3F3A status in gliomas.
Ebrahimi A; Skardelly M; Bonzheim I; Ott I; Mühleisen H; Eckert F; Tabatabai G; Schittenhelm J
Acta Neuropathol Commun; 2016 Jun; 4(1):60. PubMed ID: 27311324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
